| First Author | Zhu L | Year | 2019 |
| Journal | Int J Biol Sci | Volume | 15 |
| Issue | 13 | Pages | 2763-2773 |
| PubMed ID | 31853216 | Mgi Jnum | J:309150 |
| Mgi Id | MGI:6755672 | Doi | 10.7150/ijbs.38859 |
| Citation | Zhu L, et al. (2019) Protein arginine methyltransferase 1 is required for maintenance of normal adult hematopoiesis. Int J Biol Sci 15(13):2763-2773 |
| abstractText | Protein arginine methyltransferase 1 (PRMT1) is the predominant asymmetric (type I) methyltransferase in mammalian cells. Mounting evidence suggested that PRMT1 is essential to embryonic development and tumor pathogenesis, but its role in normal adult hematopoiesis is less studied. We used a Prmt1 conditional knockout (KO) mouse model to identify the role of PRMT1 in normal adult hematopoiesis. The results indicated that deletion of PRMT1 results in anemia and leukopenia, reducing terminal erythroid and lymphocyte differentiation. Additionally, we found a significant decrease of megakaryocyte progenitors (MkPs) compared with similarly treated littermate control mice. The frequency of short-term hematopoietic stem cells (ST-HSCs) and granulocyte-macrophage progenitors (GMPs) populations were significantly lower in PRMT1(f/f)/Mx1-CRE bone marrow (BM) compared with littermate control mice. Importantly, in-vitro replating assays and BM transplantation results revealed that PRMT1 KO results in reduced hematopoietic stem and progenitor cells (HSPCs) self-renewal capacity. Thus, we conclude that PRMT1 is required for hematopoietic differentiation and the competitive fitness of HSPCs, and we believed that PRMT1 serves as a key epigenetic regulator of normal hematopoiesis that occurs throughout life. |
